QualityDipStocks / Health Care · Diagnostics
IDEXX Laboratories IDXX
In a deep dip: 28% below its 52-week high.
A quality company trading well above our fair value estimate.
- Fair value est.
- $341.69−38%
- Market Value
- $543.91price +1%
- Off 52-wk high
- −28%
- Risk vs market
- Below marketbeta 0.80
5 bullish · 5 bearish See why
Key levels
Every level vs today’s $551.21
- Fair value est.base case$341.69−38.0%
- 52-wk lowlowest close, 1 year$504.70−8.4%
- Market Valueavg paid since Aug 4$543.91−1.3%
- PriceFri Oct 30 close$551.21you are here
- 52-wk highhighest close, 1 year$766.68+39.1%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 8.5% ±2 points. Bear = 10.5% and 6.5%; bull = 8.5% and 10.5% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is above even the bull case.
What the price implies To be worth today’s price, IDXX’s free cash flow would need to grow about 17% a year for five years; our estimate uses 9%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much IDXX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves a bit less than the market, and its own price swings are 2.5× the S&P 500’s.
- Beta vs S&P 500
- 0.80
- Volatility
- 33% vs 13% SPY
- Correlation SPY
- 0.32
- Correlation QQQ
- 0.18
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ProfitabilityReturn on equity of 74% over the last 12 months, up 9 points in two years.
ProfitabilityReturn on invested capital of 63%, above the 9.5% discount rate our DCF uses.
ValuationP/E of 38.4× is 21% below its own average of 48.5× at the last 3 fiscal year-ends.
Cash returnsFree cash flow grew 60% over the last 12 months vs the 12 months before.
TechnicalA company that passes our quality screen, now 28% off its 52-week high (deep dip).
Top bearish points 5 of 5
ValuationOur DCF fair value estimate is $341.69, 38% below the price.
ValuationEV/EBITDA of 27.3×, above the 17.0× median for the 55 Health Care companies we cover.
ValuationP/E of 38.4× vs a 29.2× median for the 86 Health Care companies we cover.
ValuationPrice / book of 27.1×, above the 5.2× median for the 93 Health Care companies we cover.
RiskReports earnings Nov 2 (consensus EPS $3.71): results can move the price sharply and reset Market Value.
Who’s talking about it
Notable investors, executives, analysts and public figures on IDEXX Laboratories in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Health Care
All fundamentals
P/E 38.4 · FCF yield 2.9% · ROE 74%
Valuation
- P/E
- 38.4×3-yr-end avg 48.5× · Health Care median 29.2×
- Price / FCF
- 34.9×
- FCF yield
- 2.9%
- EV / EBITDA
- 27.3×
- Price / sales
- 9.60×
- Price / book
- 27.11×
- Market cap
- $43.7Bprice × diluted shares
- Enterprise value
- $44.0B
Growth
- Revenue, 12 months
- $4.6B
- Sales growth, 12 months
- +12.8%vs the 12 months before
- Sales growth, 3 yrs
- +8.5%/yrfrom FY2022
- Diluted EPS, 12 months
- $14.23
- EPS growth, last FY
- +22.6%
- Net income, 12 months
- $1.1B
- Net income growth
- +16%12 months vs before
Profitability
- Gross margin
- 62.4%
- Operating margin
- 32.0%
- Net margin
- 25.0%
- FCF margin
- 27.5%
- Return on equity
- 74%
- Return on invested capital
- 63%
Balance sheet
- Cash & short-term inv.
- $197M
- Total debt
- $450M
- Net cash
- −$253M
- Debt / equity
- 0.28×
- Interest coverage
- 38.6×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $1.3B
- FCF growth, 12 months
- +60%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $1.2B2.7% of market cap
- Share count, 1 year
- −2.1%diluted shares vs a year ago
- Stock-based comp
- $63M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From IDEXX Laboratories’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $341.69 · MV $543.91 · FCF value $376.38
Assumes 8.5% growth for 5 years (revenue grew 8.5% a year FY22–FY25), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $15.82 a share (trailing 12 months to Jun 30, 2026), from the 10-Q filed Aug 4, 2026. Net debt $253M, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. We watch it daily for our three reversal signal rules while it sits in a dip.
Momentum & 52-week range
RSI 52 · 5 days −1.6%
The business
FCF $1.2B · Sales +10%
- Free cash flow, 12 months$1.2B
- Free-cash-flow yield2.7%
- Free-cash-flow margin27%
- Gross margin62%
- Operating margin32%
- Return on invested capital45%
- Return on equity73%
- Sales growth (latest quarter vs year-ago quarter)+10%
- Net debt / EBITDA0.6×
Next report
Nov 2
- DateMon Nov 2, before the open
- Consensus EPS$3.71
- Year-ago EPS$3.40
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
Get a text when IDXX fires a reversal signal
One text when a published rule fires on IDXX or any of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.